Abou-Alfa GK et al. Phase 3 randomised, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA. ASCO 2022;Abstract 379.
Andre T et al. Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). ASCO 2021;Abstract 3500.
Arnold D et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Annals of Oncology 2017;28(8):1713-29. Abstract
Bekaii-Saab T et al. KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS G12C mutation. Gastrointestinal Cancers Symposium 2022;Abstract 519.
Bekaii-Saab T et al. Practical considerations in screening for genetic alterations in cholangiocarcinoma. Annals of Oncology 2021;32(9):1111-26. Abstract
Bettegowda C et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6(224):224ra24. Abstract
Catenacci DVT et al. FIGHT: A randomized, double-blind, placebo-controlled, phase 2 study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma (GC). ASCO 2021;Abstract 4010.
Chau I et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study. ASCO 2021;Abstract LBA4001.
Ciombor KK et al. BRAF-mutated advanced colorectal cancer: A rapidly changing therapeutic landscape. J Clin Oncol 2022;JCO2102541. Abstract
Conroy T et al. Unicancer PRODIGE 24/CCTG PA6 trial: Updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC). ESMO 2021;Abstract LBA57.
Doki Y et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022;386(5):449-62. Abstract
Fakih MG et al. Sotorasib for previously treated colorectal cancers with KRAS G12C mutation (CodeBreaK100): A prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol 2022;23(1):115-24. Abstract
Finn RS et al. Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study. ASCO 2021;Abstract 4072.
Golan T et al. Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm). Gastrointestinal Cancers Symposium 2021;Abstract 420.
Harding JJ et al. Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT ‘basket’ trial. Gastrointestinal Cancers Symposium 2021;Abstract 320.
Henriksen TV et al. Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients. Gastrointestinal Cancers Symposium 2021;Abstract 11.
Hofmann MH et al. Expanding the reach of precision oncology by drugging all KRAS mutants. Cancer Discov 2022;12(4):924-37. Abstract
Janjigian YY et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet 2021;398(10294): 27-40. Abstract
Janjigian YY et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study. ESMO 2021;Abstract LBA7.
Janssen QP et al. FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: A retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst 2022;114(5):695-703. Abstract
Javle MM et al. A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (pts) with advanced biliary tract cancers. Gastrointestinal Cancers Symposium 2021;Abstract 311.
Javle M et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2021;22(9):1290-1300. Abstract
Johnson C et al. Classification of KRAS-activating mutations and the implications for therapeutic intervention. Cancer Discov 2022;12(4):913-23. Abstract
Kelly RJ et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 2021;384(13):1191-1203. Abstract
Kotaka M et al. Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan. Gastrointestinal Cancers Symposium 2022;Abstract 9.
Leidner R et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med 2022;386(22):2112-9.Abstract
Llovet JM et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18(5):293-313. Abstract
Meric-Bernstam F et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study. Gastrointestinal Cancers Symposium 2021;Abstract 299.
Moehler M et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577. ESMO 2021;Abstract 1381P.
Morris KV, Strickler JH. Use of circulating cell-free DNA to guide precision medicine in patients with colorectal cancer. Annu Rev Med 2021;72:399-413.Abstract
Qin S et al. Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial. ASCO 2022;Abstract LBA4011.
Reiss KA et al. A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC). ASCO 2022;Abstract 4021.
Sahin U et al. FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol 2021;32(5):609-19. Abstract
Schram AM et al. Zenocutuzumab, a HER2 x HER3 bispecific antibody, is effective therapy for tumors driven by NRG1 gene rearrangements. Cancer Discov 2022;12(5):1233-47. Abstract
Schram AM et al. First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors. ASCO 2021;Abstract TPS4165.
Shitara K et al. Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy, safety, and subgroup analyses from CheckMate 649. Gastrointestinal Cancers Symposium 2022;Abstract 240.
Sohal DPS et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: A phase 2 randomized clinical trial. JAMA Oncol 2021;7(3):421-7. Abstract
Strickler JH. First data for sotorasib in patients with pancreatic cancer with KRAS p. G12C mutation: A phase I/II study evaluating efficacy and safety. ASCO Plenary Series 2022;Abstract 360490.
Sun J-M et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): A randomised, placebo-controlled, phase 3 study. Lancet 2021;398(10302):759-71. Abstract
Tabernero J et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study. J Clin Oncol 2021;39(4):273-84. Abstract
Van Cutsem E et al. Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. ESMO 2021;Abstract LBA55.
Van Eijck CHJ et al. Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial. ASCO 2021;Abstract 4016.
Versteijne E et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol 2022;40(11):1220-30. Abstract
Yamaguchi K et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). Gastrointestinal Cancers Symposium 2022;Abstract 242.
Yamaguchi K et al. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the advanced gastric cancer expansion cohort. ASCO 2021;Abstract 4025.
Yau T et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23(1)77-90. Abstract
Yoo C et al. Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP). ASCO 2022;Abstract 4019.
Yoshino T et al. Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA). ASCO 2021;Abstract 2541.